Other · developed by Eupraxia Pharmaceuticals
EP-104GI is an extended-release formulation of fluticasone propionate, a corticosteroid, supplied as a powder suspended in vehicle for administration into the gastrointestinal tract. It is studied in eosinophilic esophagitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05608681 | Phase 1/2 | Eosinophilic Esophagitis | Recruiting | EPRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Eosinophilic Esophagitis
Updated Nov 15, 2026. Something wrong or missing? Report it on the EPRX page.
See EPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EPRX catalysts and pipeline →